In order to further promote the academic exchanges, transformation and application of scientific and technological achievements in the global early cancer screening industry, the 2nd ZAODX World Cancer Early Screening Conference was successfully held in Guangzhou from December 1st to 2nd. As a strategic partner, LAMH was invited to participate in the conference, and delivered a keynote speech on "Interpretation of the World's First Certificate of Liver Cancer Methylation Detection" and roundtable discussion on "How to Promote Early Tumor Screening for Everyone" and other related content in the theme forum.
The conference is the largest event in the field of early tumor screening, and the conference invited Academician Zhong Nanshan, academician of the Chinese Academy of Engineering, winner of the "Medal of the Republic", director of the Guangzhou National Laboratory, executive deputy director of the Guangdong Provincial Working Committee for the Care of the Next Generation, chief expert of the Guangdong Provincial Health Care Association, former party secretary of the Guangdong Provincial Department of Health, former director of the Guangdong Provincial Bureau of Press, Publication, Radio, Film and Television, and Professor Barry Marshall, winner of the 2005 Nobel Prize in Chemistry, to deliver speeches. At the same time, many guests were also invited to attend the meeting, including Academician Fan Daiming, Academician of the Chinese Academy of Engineering and Chairman of the China Anti-Cancer Association, and Professor Chen Wanqing, Director of the Office of Early Diagnosis and Early Treatment of Cancer of the National Cancer Center, to discuss the development of the early cancer screening industry.
On the afternoon of December 2, Professor Chen Wanqing, Director of the Office of Early Diagnosis and Early Treatment of Cancer of the National Cancer Center, delivered a keynote speech on "The Current Situation and Future of Early Cancer Screening in China" at the Forum on Cancer Screening and Early Diagnosis and Early Treatment, in which he shared the burden of cancer in China, the progress of international screening of liver cancer, and the progress of domestic screening of liver cancer. Professor Chen Wanqing introduced a new liver cancer screening method, liver cancer methylation detection, which has a sensitivity and specificity of more than 95%, and is non-invasive, non-invasive, and easy to operate. Compared with traditional methods (ultrasound and AFP), it is a very promising liver cancer screening test.
On the afternoon of December 1, at the Tumor Early Screening Commercialization Conference, Mr. Long Hao, Product Director of LAMH Health, shared the world's first liver cancer methylation detection kit approved by NMPA registration and approval launched by LAM, and gave a wonderful speech on the theme of "Interpretation of the World's First Certificate of Liver Cancer Methylation Detection".Second, why methylation detection was chosen as a technical approach for product developmentThirdly, the data performance of the registration clinical trial of the LAMH liver cancer methylation detection kit of Laimeng Health;Fourth, the potential beneficiaries of early screening of liver cancer. An in-depth interpretation of the world's first liver cancer methylation kit obtained by LAMH Health. Liver Cancer Methylation Detection-BMPR1A PLAc8 Gene Methylation Detection Kit (Gambekang) is non-invasive**, the results are accurate and reliable, and the sensitivity for detecting liver cancer is as high as 9542% with a specificity of up to 9602%。
On the morning of December 1st, at the roundtable forum "How to promote early tumor screening for everyone", Ms. Ding Yaqing, vice president of LAMH Health, answered and shared the question of "how to make innovative technology benefit more people".Second, the R&D cost of the product is low, moderate, and can benefit most peopleThird, the ease of use of the product also needs to be considered;Fourth, the development of early tumor screening requires the attention and support of all sectors of society, the publicity and popularization of early screening enterprise products, the improvement of people's awareness of testing, and the support of relevant departments. Through the above strategies, we can help realize the vision of early cancer screening for everyone.
L&M Health is a full-fledged cancer early screening and diagnosis company in China and the United States, including technology development, production, NMPA FDA approval and commercialization. It launched its first liver cancer early detection products in China and the United States, Ganbekang and Helioliver, providing early, accurate, accessible and simple screening and diagnosis solutions for liver cancer, changing the path of clinical screening, diagnosis and monitoring of liver cancer, and addressing the unmet clinical and health needs in China and the United States through value-based medicine. The company has 66 invention patents in international PCT and China and the United States, and is also the first Chinese cancer early screening and early diagnosis enterprise to obtain the FDA breakthrough medical device certificate, and on June 20, 2023, Guangzhou Youze Biotechnology, a GMP entity of Lyman Group, obtained the world's first clinical trial early screening and early diagnosis certificate for liver cancer. Its U.S. company, Helio, is the first and only company in the world to receive the CPT** and insurance pricing ($660, twice a year) for early liver cancer screening in the United States. On the road to the future, LAMH is committed to pushing early tumor screening to a new height, and truly realizing early tumor screening that is accessible to everyone.